Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc. - Common Stock (NQ:SGEN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
3 Top Stocks to Buy in October and Hold Forever
Check out these three blue chip buys playing crucial roles in America's $6 trillion healthcare opportunity. 
Via The Motley Fool
If You Invested $100 In This Stock 20 Years Ago, You Would Have $3,400 Today
Via Benzinga
5 Stocks That Have Massive Upside According to Analysts
Analyst ratings are frequently a solid predictor of future stock price movement; here are five stocks that analysts believe have massive upside. 
Via MarketBeat
Don’t Miss the Boom: 3 Pharma Stocks Set to Explode Higher
These pharma stocks could boom in the coming years, riding their diversified pipelines with massive addressable markets higher. 
Via InvestorPlace
September's Shakeout: S&P 500, Nasdaq 100 See Just 13% Of Stocks Above 50-Day Average
The September market downturn is spreading like wildfire across various sectors, with only a handful of stocks managing to maintain the positive trend seen in recent months. 
Via Benzinga
Topics Stocks
Exposures US Equities
Seagen Unusual Options Activity
Via Benzinga
Seagen Inc. (NASDAQ: SGEN) Climbs to New 52-Week High
Via Investor Brand Network
(SGEN) - Analyzing Seagen's Short Interest
Via Benzinga
Why Is Seagen Stock Trading Higher Today?
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC:  
Via Benzinga
Seagen Inc. (NASDAQ: SGEN) Sets New 52-Week High in Friday Session
Via Investor Brand Network
Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer
The companies tested a key combination in patients with previously untreated bladder cancer. 
Via Investor's Business Daily
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
From Seagen Inc.
Via Business Wire
Check Out What Whales Are Doing With SGEN
Via Benzinga
Check Out What Whales Are Doing With SGEN
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $16,000 Today
Via Benzinga
Check Out What Whales Are Doing With SGEN
Via Benzinga
Flee to Healthcare Stocks if Recession Rears its Head?
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends. 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Shares of Iovance Biotherapeutics Dropped Thursday
The biotech stock's lead therapy is looking at some competition. 
Via The Motley Fool
The 3 Most Undervalued Pharma Stocks to Buy in September 2023
Investing in pharmaceutical industry always carries risk, but several pharma stocks have an attractive risk/reward valuation right now. 
Via InvestorPlace
Looking Into Seagen's Recent Short Interest
Via Benzinga
Here's How Much You Would Have Made Owning Seagen Stock In The Last 10 Years
Via Benzinga
Why Is Cancer Focused Nurix Therapeutics Stock Trading Higher Today?
Nurix Therapeutics Inc (NASDAQ: NRIX) has entered into a multi-year, multi-target strategic collaboration agreement with Seagen Inc (NASDAQ: SGEN) to advance a new class of medicines called... 
Via Benzinga
Pyxis Oncology M&A Spotlight Signals Potential Growth Amidst Competitive ADC Landscape: Analyst
RBC Capital Markets has initiated coverage on Pyxis Oncology Inc (NASDAQ: PYXS) with an Outperform rating and a  
Via Benzinga
Why Shares of Zai Lab Limited Were Jumping on Tuesday
Zai Lab's shares benefited from positive clinical trial news. 
Via The Motley Fool
Encouraging Data From Seagen/Genmab's Cervical Cancer Study - Tivdak Success Sets Stage For New Indications
Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) released topline data from the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on... 
Via Benzinga
Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone
From Seagen Inc.
Via Business Wire
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
From Genmab A/S
Via Business Wire
Ambrx Biopharma Has Surged 483% This Year. But It Could Just Be Getting Started.
The company has another update on its prostate cancer program that could further prod shares. 
Via Investor's Business Daily
3 Fantastic Stocks to Buy in a New Bull Market
These stocks could be just the ticket if a sustained new bull market is beginning. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.